Cardinal Health Lifts FY25 EPS Outlook, Sees Growth Despite Tariff Risks

1. CAH reported Q3 2025 adjusted EPS of $2.35, exceeding expectations. 2. Sales of $54.9 billion missed consensus estimates of $55.35 billion. 3. Pharmaceutical and Specialty Solutions sales remained flat at $50.6 billion. 4. Raised FY 2025 adjusted EPS guidance to $8.05-$8.15 from $7.85-$8.00. 5. GMPD profit outlook narrowed; expectations remain stable amid macro uncertainties.